EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Serum chemokine CC ‐motif ligand 17 is a predictive marker of severe COVID ‐19 in haemodialysis patients: A retrospective observational study

Hiroko Beppu, Tatsuya Fukuda iD, Naoya Otsubo, Tomoko Kawanishi, Toshie Ogawa, Yasutomo Abe, Mariko Endo, Tomohide Hanawa, Chise Sugita, Yoshiaki Kikkawa, Shuji Hatakeyama, Tetsuya Yamada und 1 weitere

Nephrology · 2023

DOI: 10.1111/nep.14151 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nephrology, 2023. Verfasst von Hiroko Beppu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Tokyo Metropolitan Okubo Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Tokyo Metropolitan Okubo Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Maintenance haemodialysis (HD) patients are at higher risk for severe coronavirus disease 2019 (COVID‐19). Because of a limited number of facilities that can provide inpatient treatment for COVID‐19 and HD, it is important to identify HD patients who are at high risk for severe COVID‐19. For mild to moderate COVID‐19 patients, chemokine CC‐motif ligand 17 (CCL17) was reported to be a predictive marker for severe COVID‐19; however, the validity of CCL17 among HD patients is unknown.

Methods

This retrospective observational study enrolled 107 HD patients with mild or moderate COVID‐19 at hospitalization (mean age 70.1 ± 15.1 years; 71.0% male). Receiver operating characteristic and logistic regression analyses were used to examine the predictive validity of indices for severe COVID‐19.

Results

During hospitalization, 32 patients developed severe COVID‐19. Serum CCL17 collected at admission exhibited a higher area under the curve value (0.818) compared with that of other indicators including lactate dehydrogenase and C‐reactive protein for the prediction of severe COVID‐19. The optimal cut‐off value for CCL17 was 150.5 pg/mL. A multi‐variate logistic analysis revealed that CCL17 (above 150.5 pg/mL) was significantly associated with severe COVID‐19 (Odds ratio, 0.063; 95% Confidence interval [CI], 0.017–0.227; p < .001) even after adjustment for covariates. The addition of the CCL17 to a model consisting of vaccination status, albumin, blood urea nitrogen, C‐reacting protein and lactate dehydrogenase significantly improved classification performance for severe COVID‐19 using the net reclassification (1.16, 95% CI: 0.82–1.50, p < .001) and integrated discrimination (0.18, 95% CI: 0.09–0.26, p < .001) improvement.

Conclusion

CCL17 levels in HD patients with mild or moderate COVID‐19 predict risk of developing severe COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AgedAged, 80 and overFemaleHumansMaleMiddle AgedChemokinesCholecalciferolLactate DehydrogenasesLigandsRenal DialysisRetrospective StudiesSARS-CoV-2Chemokine CCL17

Stichwörter der Autor:innen

COVID-19SARS-CoV-2chemokine CC-motif ligand 17haemodialysisthymus and activation-regulated chemokine

Substanzen

ChemokinesCholecalciferolLactate DehydrogenasesLigandsCCL17 protein, humanChemokine CCL17

Autor:innen und Institutionen

  • Department of Nephrology, Tokyo Metropolitan Okubo Hospital, Tokyo, Japan.
  • Department of Cooperative Graduate School, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
  • Department of Endocrinology and Metabolism, Tokyo Metropolitan Okubo Hospital, Tokyo, Japan.
  • Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
  • Department of Pulmonary Medicine, Tokyo Metropolitan Okubo Hospital, Tokyo, Japan.
  • Department of Basic Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.

ORCID-Profile: Tatsuya Fukuda

Förderung

  • Tokyo Metropolitan Okubo Hospital

Zitieren

APA

Beppu, H., Fukuda, T., Otsubo, N., Kawanishi, T., Ogawa, T., Abe, Y., Endo, M., Hanawa, T., Sugita, C., Kikkawa, Y., Hatakeyama, S., Yamada, T., & Wakai, S. (2023). Serum chemokine CC ‐motif ligand 17 is a predictive marker of severe COVID ‐19 in haemodialysis patients: A retrospective observational study. Nephrology. https://doi.org/10.1111/nep.14151

Vancouver

Beppu H, Fukuda T, Otsubo N, Kawanishi T, Ogawa T, Abe Y, et al. Serum chemokine CC ‐motif ligand 17 is a predictive marker of severe COVID ‐19 in haemodialysis patients: A retrospective observational study. Nephrology. 2023. doi:10.1111/nep.14151

BibTeX
@article{Beppu2023,
  author = {Beppu, Hiroko and Fukuda, Tatsuya and Otsubo, Naoya and Kawanishi, Tomoko and Ogawa, Toshie and Abe, Yasutomo and Endo, Mariko and Hanawa, Tomohide and Sugita, Chise and Kikkawa, Yoshiaki and Hatakeyama, Shuji and Yamada, Tetsuya and Wakai, Sachiko},
  title = {Serum chemokine CC ‐motif ligand 17 is a predictive marker of severe COVID ‐19 in haemodialysis patients: A retrospective observational study},
  journal = {Nephrology},
  year = {2023},
  doi = {10.1111/nep.14151}
}
Kostenlos starten →